Supplementary Figure 7 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Matias Casás-Selves,Jihye Kim,Zhiyong Zhang,Barbara A. Helfrich,Dexiang Gao,Christopher C. Porter,Hannah A. Scarborough,Paul A. Bunn,Daniel C. Chan,Aik Choon Tan,James DeGregori

DOI: https://doi.org/10.1158/0008-5472.22391496.v1

2023-01-01

Abstract:PDF file - 76K, Second xenograft experiment utilizing a different shRNA for TNKS1

What problem does this paper attempt to address?

Supplementary Figure 5 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Matias Casás-Selves,Jihye Kim,Zhiyong Zhang,Barbara A. Helfrich,Dexiang Gao,Christopher C. Porter,Hannah A. Scarborough,Paul A. Bunn,Daniel C. Chan,Aik Choon Tan,James DeGregori

DOI: https://doi.org/10.1158/0008-5472.22391502.v1

2023-01-01

Abstract:PDF file - 222K, Demonstration that beta-catenin or TCF-4 knockdown results in enhanced sensitivity of NSCLC cells to gefitinib treatment, that beta-catenin or TCF-4 knockdowns reduce the expression of the corresponding protein, that there is minimal correlation between the expression of canonical Wnt target genes and gefitinib sensitivity for a panel of NSCLC cell lines, that there is no significant correlation of SLuGs with gefitinib induced genes, and that SLuGs are not enriched in lung cancer specific genes
Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai Tran,Robert J.G. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun K. Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22446704

2023-01-01

Abstract:PDF file - 66K, CDH1 probes vary in their accuracy and dynamic range
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Hannah A. Scarborough,Barbara A. Helfrich,Matias Casás-Selves,Alwin G. Schuller,Shaun E. Grosskurth,Jihye Kim,Aik-Choon Tan,Daniel C. Chan,Zhiyong Zhang,Vadym Zaberezhnyy,Paul A. Bunn,James DeGregori

DOI: https://doi.org/10.1158/1078-0432.22463952

2023-01-01

Abstract:Supplementary methods and materials
Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jing Sun,Kwangho Lee,Aleksandr Dubrovskiy,Matthew Labenski,Zhendong Zhu,Zhigang Wang,Michael Sheets,Thia St Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,Mariana Nacht,Russell C. Petter,William Westlin,Kevin Lin,Sarah Jaw-Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoe Weaver,William Pao,Juswinder Singh,Andrew D. Simmons,Thomas C. Harding,Andrew Allen

DOI: https://doi.org/10.1158/2159-8290.22530291.v1

2023-01-01

Abstract:Supplementary Figure 7 - PDF file 352K, H&E and immunohistochemical (Ki67) staining of tumors derived from EGFR mutant GEM models
Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jun Sun,Kwang‐Ho Lee,Aleksandr Dubrovskiy,Matthew Labenski,Zhihong Zhu,Zhigang Wang,Michael Sheets,Thomas N. Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,Mariana Nacht,Russell C. Petter,William Westlin,Kevin Lin,Sarah Jaw‐Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoë Weaver,William Pao,Juswinder Singh,Andrew Simmons,Thomas C. Harding,Andrew J. Allen

DOI: https://doi.org/10.1158/2159-8290.22530288.v1

2023-01-01

Abstract:Supplementary Figure 8 - PDF file 215K, Photomicrographs of CO-1686 resistant NCI-H1975 cell (COR) clones and quantification of EGFR siRNA knockdown in COR clones
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jun Sun,Kwang‐Ho Lee,Aleksandr Dubrovskiy,Matthew Labenski,Zhihong Zhu,Zhigang Wang,Michael Sheets,Thomas N. Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,Mariana Nacht,Russell C. Petter,William Westlin,Kevin Lin,Sarah Jaw‐Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoë Weaver,William Pao,Juswinder Singh,Andrew D. Simmons,Thomas C. Harding,Andrew J. Allen

DOI: https://doi.org/10.1158/2159-8290.22530285.v1

2023-01-01

Abstract:Supplementary Figure 9 - PDF file 168K, NCI-H1975 parental and CO-1686 resistant clones cluster into distinct groups using an RNA-based EMT signature
Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Amanda Herzog,Yansong Bian,Robert Vander Broek,Bradford Hall,Jamie Coupar,Hui Cheng,Anastasia L. Sowers,John D. Cook,James B. Mitchell,Zhong Chen,Ashok B. Kulkarni,Carter Van Waes

DOI: https://doi.org/10.1158/1078-0432.22445265

2023-01-01

Abstract:PDF file - 1957K, Treatment in UM-SCC xenograft and Tgfbr1/Pten KO mice.
Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross,Susan E. Ashton,Serban Ghiorghiu,Cath Eberlein,Caroline A. Nebhan,Paula J. Spitzler,Jonathon P. Orme,M. Raymond V. Finlay,Richard A. Ward,Martine J. Mellor,Gareth Hughes,Amar Rahi,Vivien N. Jacobs,Monica Red Brewer,Eiki Ichihara,Jing Sun,Hailing Jin,Peter Ballard,Katherine Al-Kadhimi,Rachel Rowlinson,Teresa Klinowska,Graham H.P. Richmond,Mireille Cantarini,Dong-Wan Kim,Malcolm R. Ranson,William Pao

DOI: https://doi.org/10.1158/2159-8290.22532204

2023-01-01

Abstract:PDF file - 235KB, Activity of AZD9291 and metabolites against rare EGFR mutations using cellular phosphorylation assays.
Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jun Sun,Kwang‐Ho Lee,Aleksandr Dubrovskiy,Matthew Labenski,Zhihong Zhu,Zhigang Wang,Michael Sheets,Thomas N. Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,Mariana Nacht,Russell C. Petter,William Westlin,Kevin Lin,Sarah Jaw‐Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoë Weaver,William Pao,Juswinder Singh,Andrew Simmons,Thomas C. Harding,Andrew J. Allen

DOI: https://doi.org/10.1158/2159-8290.22530309.v1

2023-01-01

Abstract:Supplementary Figure 11 - PDF file 255K, Analysis of the role of AXL in mediating CO-1686 resistance in COR cell clones.
Supplementary Figure 6 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross,Susan E. Ashton,Serban Ghiorghiu,Cath Eberlein,Caroline A. Nebhan,Paula J. Spitzler,Jonathon P. Orme,M. Raymond V. Finlay,Richard A. Ward,Martine J. Mellor,Gareth Hughes,Amar Rahi,Vivien N. Jacobs,Monica Red Brewer,Eiki Ichihara,Jing Sun,Hailing Jin,Peter Ballard,Katherine Al-Kadhimi,Rachel Rowlinson,Teresa Klinowska,Graham H.P. Richmond,Mireille Cantarini,Dong-Wan Kim,Malcolm R. Ranson,William Pao

DOI: https://doi.org/10.1158/2159-8290.22532195.v1

2023-01-01

Abstract:PDF file - 312KB, Efficacy of AZD9291 in H3255, PC-9VanR and A431 xenograft models. Weight loss data for chronically dosed AZD9291 in PC-9 and H1975 xenograft models.
Supplementary Figure 5 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis

Yaqing Zhang,John P. Morris,Wei Yan,Heather K. Schofield,Austin Gurney,Diane M. Simeone,Sarah E. Millar,Timothy Hoey,Matthias Hebrok,Marina Pasca di Magliano

DOI: https://doi.org/10.1158/0008-5472.22394955.v1

2023-01-01

Abstract:PDF file - 4422K, Supplemental Figure 5. Survival curve of KC and KDC mice. PDA in KC and KDC mice.
Supplementary Figure 3 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Tsuyoshi Yoshida,Guolin Zhang,Matthew A. Smith,Alex S. López,Yun Bai,Jiannong Li,Bin Fang,John M. Koomen,Bhupendra Rawal,Kate Fisher,Ann Y. Chen,Michiko Kitano,Yume Morita,Haruka Yamaguchi,K. Shibata,Takafumi Okabe,Isamu Okamoto,Kazuhiko Nakagawa,Eric B. Haura

DOI: https://doi.org/10.1158/1078-0432.22451534

2023-01-01

Abstract:PDF file - 387KB, Effects of ligands exposure with or without EGFR-TKI in PC9 and PC9GR cells. A-F: PC9 (A, C, and E) or PC9GR cells (B, D, and F) were incubated for 1 hour in the absence or presence of 100 nM erlotinib (A, C, and E) or afatinib (B, D, and F) with indicated concentrations of HGF (A and B), IGF1 (C and D), or Gas6 (E and F). Cell lysates were subjected to protein expression analysis with antibodies to pMET (A and B), IGF1R (C and D), or pAXL (E and F) along with pEGFR, pAkt, pErk, and antibodies to β-actin as a loading control.
Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jun Sun,Kwang‐Ho Lee,Aleksandr Dubrovskiy,Matthew Labenski,Zhihong Zhu,Zhigang Wang,Michael Sheets,Thomas N. Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,Mariana Nacht,Russell C. Petter,William Westlin,Kevin Lin,Sarah Jaw‐Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoë Weaver,William Pao,Juswinder Singh,Andrew Simmons,Thomas C. Harding,Andrew J. Allen

DOI: https://doi.org/10.1158/2159-8290.22530303.v1

2023-01-01

Abstract:Supplementary Figure 3 - PDF file 295K, Activity of CO-1686 against rare lung-cancer associated EGFR mutants
Supplementary Figure 4 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Takeshi Yoshida,Guolin Zhang,Matthew A. Smith,Alex S. Lopez,Yun Bai,Jiannong Li,Bin Fang,John Koomen,Bhupendra Rawal,Kate J. Fisher,Ann Y. Chen,Michiko Kitano,Yume Morita,Haruka Yamaguchi,Kiyoko Shibata,Takafumi Okabe,Isamu Okamoto,Kazuhiko Nakagawa,Eric B. Haura

DOI: https://doi.org/10.1158/1078-0432.22451531

2023-01-01

Abstract:PDF file - 139KB, Effects of ligands exposure with or without EGFR-TKI in PC9 and PC9GR cells. A-F: PC9 (A, C, and E) or PC9GR cells (B, D, and F) were incubated for 1 hour in the absence or presence of 100 nM erlotinib (A, C, and E) or afatinib (B, D, and F) with indicated concentrations of HGF (A and B), IGF1 (C and D), or Gas6 (E and F). Cell lysates were subjected to protein expression analysis with antibodies to pMET (A and B), IGF1R (C and D), or pAXL (E and F) along with pEGFR, pAkt, pErk, and antibodies to β-actin as a loading control.
Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Lenka Sinik,Katherine A. Minson,John J. Tentler,Jacqueline Carrico,Stacey M. Bagby,William A. Robinson,Rotem Kami,Tal Burstyn‐Cohen,S. Gail Eckhardt,Xiaodong Wang,Stephen V. Frye,H. Shelton Earp,Deborah DeRyckere,Douglas K. Graham

DOI: https://doi.org/10.1158/1535-7163.22508884.v1

2023-01-01

Abstract:Supplemental Figure 2 shows impact of UNC2025 on colony forming potential.
Supplementary Figure 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross,Susan E. Ashton,Serban Ghiorghiu,Cath Eberlein,Caroline A. Nebhan,Paula J. Spitzler,Jonathon P. Orme,M. Raymond V. Finlay,Richard A. Ward,Martine J. Mellor,Gareth Hughes,Amar Rahi,Vivien N. Jacobs,Monica Red Brewer,Eiki Ichihara,Jing Sun,Hailing Jin,Peter Ballard,Katherine Al-Kadhimi,Rachel Rowlinson,Teresa Klinowska,Graham H.P. Richmond,Mireille Cantarini,Dong-Wan Kim,Malcolm R. Ranson,William Pao

DOI: https://doi.org/10.1158/2159-8290.22532210

2023-01-01

Abstract:PDF file - 107KB, Mass Spectrometry study showing covalent binding of AZD9291 to cysteine 797 in EGFR T790M.
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

K. Mark Parnell,Jason M. Foulks,Rebecca N. Nix,Adrianne Clifford,Jeremy Bullough,Bin Luo,Anna V. Senina,David Vollmer,Jihua Liu,Virgil McCarthy,Yong Xu,Michael Saunders,Xiaohui Liu,Scott Pearce,Kevin B. Wright,Marc O’Reilly,Michael V. McCullar,Koc-Kan Ho,Steven B. Kanner

DOI: https://doi.org/10.1158/1535-7163.22499760.v1

2023-01-01

Abstract:Supplementary Figure Legends - PDF file 41K, Legends for supplemental figures 1-4
Supplementary Figure 2 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis

Yaqing Zhang,John P. Morris,Wei Yan,Heather K. Schofield,Austin Gurney,Diane M. Simeone,Sarah E. Millar,Timothy Hoey,Matthias Hebrok,Marina Pasca di Magliano

DOI: https://doi.org/10.1158/0008-5472.22394964.v1

2023-01-01

Abstract:PDF file - 6297K, Supplemental Figure 2. Pancreatic histology in DKK1 mice on doxy; KC and KDC mice without doxy.

Supplementary Figure 7 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Supplementary Figure 5 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 6 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Supplementary Figure 5 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis

Supplementary Figure 3 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 4 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Supplementary Figure 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

Supplementary Figure 2 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis